VISEN Pharmaceuticals
HHKEX:256116.97
HKD
-0.34
(-1.96%)
ISIN
KYG93Y5D1039
CUSIP
G93Y5D103
Return %
Stock
S&P 500
1Y
-58.41
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- An Bang Lu
- Full Time Employees
- 82
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Building B, Hengtai Lixiang Chuangxin Tower Suzhou JS China 215000
- IPO Date
- Mar 21, 2025
- Website
- visenpharma.com
- Similar Companies
- Business
- VISEN Pharmaceuticals (2561.HK) is a biopharmaceutical company focused on the research, development, and commercialization of innovative endocrine therapies in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. Incorporated in 2018 and headquartered in Suzhou, China, the company advances a pipeline of long-acting prodrug therapies utilizing TransCon technology; its lead product candidates include lonapegsomatropin (Skytrofa), a once-weekly long-acting growth hormone replacement therapy that has completed Phase III trials for pediatric growth hormone deficiency; navepegritide (TransCon CNP), a long-acting prodrug of C-type natriuretic peptide that has completed Phase II trials for achondroplasia; and palopegteriparatide (Yorvipath or TransCon PTH), a once-daily parathyroid hormone replacement therapy in Phase III trials for chronic hypoparathyroidism. VISEN targets unmet needs in endocrinology diseases such as growth hormone deficiency, hypoparathyroidism, and achondroplasia, serving pediatric and adult patients through disruptive, patient-centric treatments. Recent developments include a successful initial public offering on the Hong Kong Stock Exchange in March 2025 raising approximately $86.5 million; a new commercial supply framework agreement with Ascendis Europe, effective June 2025 through December 2027, for drug packages, auto-injectors, and ancillary products to support lonapegsomatropin commercialization; and strategic collaborations with Shanghai Pharmaceutical, United Family Healthcare, and prior investors including Ascendis Pharma, Sofinnova Ventures, Vivo Capital, and others following a total funding of $190 million prior to IPO.